NRF2 Gene

Introduction

Pathway Diagram

flowchart TD
    NF2EL2["NF2EL2<br/>(NRF2 gene)"] -->|"encodes"| NRF2["NRF2<br/>(Master antioxidant<br/>transcription factor)"]
    
    KEAP1_gene["KEAP1<br/>(gene)"] -->|"encodes"| KEAP1["KEAP1<br/>(Kelch-like ECH-associated<br/>protein 1)"]
    KEAP1 -->|"inhibits"| NRF2
    NRF2 -->|"inhibits"| KEAP1
    
    kaempferol["Kaempferol<br/>(Natural activator)"] -->|"activates"| NRF2
    PGC1A["PGC-1alpha<br/>(Metabolic regulator)"] -->|"activates"| NRF2
    TGR5["TGR5<br/>(G-protein coupled<br/>receptor)"] -->|"activates"| NRF2
    ML385["ML385<br/>(NRF2 inhibitor)"] -->|"inhibits"| NRF2
    
    NRF2 -->|"activates"| ARE["ARE<br/>(Antioxidant Response<br/>Elements)"]
    ARE -->|"transcriptional<br/>activation"| HMOX1["HMOX1<br/>(Heme oxygenase-1)"]
    ARE -->|"transcriptional<br/>activation"| NQO1["NQO1<br/>(NAD(P)H quinone<br/>oxidoreductase)"]
    ARE -->|"transcriptional<br/>activation"| GCLC["GCLC/GCLM<br/>(Glutathione synthesis<br/>enzymes)"]
    ARE -->|"transcriptional<br/>activation"| SLC7A11["SLC7A11<br/>(Cystine/glutamate<br/>antiporter)"]
    
    NRF2 -->|"regulates"| SOD["SOD<br/>(Superoxide<br/>dismutase)"]
    NRF2 -->|"regulates"| CATALASE["Catalase<br/>(H2O2 detoxification)"]
    
    HMOX1 -->|"reduces"| OXIDATIVE_STRESS["Oxidative Stress<br/>(Neuronal damage)"]
    GCLC -->|"produces"| REDOX_HOMEOSTASIS["Redox Homeostasis<br/>(Cellular protection)"]
    SOD -->|"maintains"| REDOX_HOMEOSTASIS
    CATALASE -->|"maintains"| REDOX_HOMEOSTASIS
    
    REDOX_HOMEOSTASIS -->|"protects against"| NEURODEGENERATION["Neurodegeneration<br/>(Disease outcome)"]

    style NRF2 fill:#006494
    style KEAP1 fill:#4a1a6b
    style kaempferol fill:#1b5e20
    style PGC1A fill:#4a1a6b
    style TGR5 fill:#4a1a6b
    style ML385 fill:#ef5350
    style ARE fill:#1b5e20
    style HMOX1 fill:#1b5e20
    style NQO1 fill:#1b5e20
    style GCLC fill:#1b5e20
    style SLC7A11 fill:#1b5e20
    style SOD fill:#1b5e20
    style CATALASE fill:#1b5e20
    style OXIDATIVE_STRESS fill:#ef5350
    style REDOX_HOMEOSTASIS fill:#1b5e20
    style NEURODEGENERATION fill:#5d4400

Nrf2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

title: NRF2 Gene

Overview

NFE2L2 (commonly known as NRF2) is the master regulator of antioxidant response and cellular defense against oxidative stress. It is a critical therapeutic target for neurodegenerative diseases characterized by oxidative damage. By activating over 200 target genes, NRF2 coordinates the cellular defense against reactive oxygen species (ROS), electrophiles, and xenobiotics^{1The NRF2 regulatory network and its dysregulation in toxicity, injury, and disease2020 · Annu Rev Pharmacol Toxicol · PMID 31415175Open reference}.

Gene Structure

The NRF2 gene (NFE2L2) spans approximately 22 kb on chromosome 2q31.3 and contains 5 exons. The NRF2 protein contains 605 amino acids and is characterized by several functional domains:

• Neh (Nrf2-ECH) Domains: Six conserved domains (Neh1-Neh6) that mediate protein-protein interactions

• Neh1 (aa 1-100): Basic leucine zipper (bZIP) region for DNA binding and heterodimerization with small Maf proteins

• Neh2 (aa 111-203): Contains the ETGE and DLG motifs for KEAP1 binding and negative regulation

• Neh3 (aa 211-316): Transactivation domain interacting with transcriptional coactivators

• Neh4/Neh5 (aa 317-400): Additional transactivation domains

• Neh6 (aa 401-493): Beta-transducin repeat-containing protein (β-TrCP) recognition motif for proteasomal degradation

Protein Structure

NRF2 is a basic leucine zipper (bZIP) transcription factor. Under homeostatic conditions, NRF2 is sequestered in the cytoplasm by KEAP1 (Kelch-like ECH-associated protein 1), which acts as an adaptor for the Cullin 3-based E3 ubiquitin ligase complex. KEAP1 senses oxidative stress through its cysteine residues (C151, C273, C288), leading to NRF2 release and nuclear translocation^{2KEAP1-NRF2 signaling in the heart: From basic science to clinical translation2021 · Nat Rev Cardiol · PMID 34267371Open reference}.

Normal Function

Antioxidant Response

Under basal conditions, NRF2 is constantly ubiquitinated and degraded by the proteasome. Upon oxidative or electrophilic stress, KEAP1 cysteine residues are modified, preventing NRF2 degradation. Stabilized NRF2 translocates to the nucleus, heterodimerizes with small Maf proteins, and binds to the Antioxidant Response Element (ARE: 5’-TGACnnnGC-3’) in the promoter regions of target genes.

Target Gene Categories

NRF2 regulates genes involved in:

Anti-inflammatory Effects

NRF2 exerts anti-inflammatory effects through:

• Inhibition of NF-κB transcriptional activity

• Suppression of pro-inflammatory cytokine expression

• Regulation of NLRP3 inflammasome

• Modulation of microglia activation

Disease Associations

Alzheimer’s Disease

NRF2 activation is protective in AD through multiple mechanisms^{3NRF2 as a therapeutic target in neurodegenerative diseases2020 · Neurotherapeutics · PMID 31808092Open reference}:

• Aβ Clearance: NRF2 enhances expression of detoxifying enzymes that facilitate Aβ clearance

• Tau Pathology: NRF2 activation reduces tau hyperphosphorylation through GSK-3β inhibition

• Neuroinflammation: NRF2 inhibits microglial activation and pro-inflammatory cytokine production

• Mitochondrial Function: NRF2-PGC-1α axis promotes mitochondrial biogenesis impaired in AD

• Clinical Evidence: NRF2 activity is reduced in AD brains, and NRF2 activators are in clinical trials

Parkinson’s Disease

NRF2 is a major therapeutic target in PD due to:

• Dopaminergic Neuron Vulnerability: High oxidative stress in substantia nigra requires robust NRF2 response

• Mitochondrial Toxins: MPTP, rotenone, and 6-OHDA activate NRF2, but response is inadequate in PD

• LRRK2 Interaction: Mutant LRRK2 impairs NRF2 nuclear translocation

• GBA Mutations: Reduced NRF2 activity in GBA-associated PD

• Therapeutic Evidence: Sulforaphane and other NRF2 activators protect dopaminergic neurons in models

Huntington’s Disease

In HD, NRF2 dysregulation contributes to disease progression:

• Transcriptional Dysfunction: Mutant huntingtin impairs NRF2 nuclear localization

• Oxidative Stress: NRF2 activation reduces oxidative damage and improves motor function

• Mitochondrial Biogenesis: PGC-1α activation through NRF2 improves mitochondrial function

• Therapeutic Potential: NRF2 activators (sulforaphane, bardoxolone methyl) show promise in preclinical models

Amyotrophic Lateral Sclerosis

NRF2 alterations in ALS include:

• SOD1 Mutations: Oxidative stress from mutant SOD1 activates NRF2

• C9orf72: Reduced NRF2 activity due to hexanucleotide repeat toxicity

• Astrocyte Dysfunction: Impaired NRF2 response in ALS astrocytes

• Therapeutic Targeting: NRF2 activators may enhance astrocyte-mediated neuroprotection

Multiple Sclerosis

NRF2 plays protective roles in MS:

• Demyelination: NRF2 activation protects oligodendrocytes from oxidative damage

• Neuroinflammation: NRF2 inhibits inflammatory cascades in MS

• Therapeutic Potential: Dimethyl fumarate (Tecfidera), an NRF2 activator, is an approved MS treatment

Stroke

NRF2 activation is protective in ischemic stroke:

• Blood-Brain Barrier: NRF2 protects BBB integrity after ischemia

• Infarct Reduction: NRF2 activators reduce infarct size in preclinical models

• Rehabilitation: NRF2 contributes to functional recovery through antioxidant effects

Expression Pattern

NRF2 is expressed in neurons and glia throughout the brain:

High Expression Regions: Cerebral cortex, hippocampus (CA1-CA3, dentate gyrus), basal ganglia (striatum, substantia nigra), cerebellum (Purkinje cells), spinal cord motor neurons.

Expression is inducible by oxidative stress, electrophiles, and neurotrophic factors (BDNF, NGF).

Molecular Mechanisms

KEAP1-NRF2 Pathway

1. Basal State: NRF2 bound to KEAP1 → Cul3 ubiquitination → proteasomal degradation

2. Stress Sensing: Oxidants/electrophiles modify KEAP1 cysteine residues (C151, C273, C288)

3. Release: NRF2 escapes ubiquitination, accumulates in cytoplasm

4. Nuclear Import: NRF2 translocates to nucleus via nuclear localization signals

5. Transcription: NRF2-small Maf heterodimers bind ARE, activate transcription

6. Feedback: NRF2 upregulates KEAP1, establishing negative feedback loop

Cross-talk with Other Pathways

• NF-κB: NRF2 inhibits NF-κB through p65 sequestration and antioxidant gene expression

• AMPK: Energy stress activates AMPK, which can enhance NRF2 activity

• mTOR: Hyperactivation suppresses NRF2; mTOR inhibitors enhance NRF2 signaling

• PGC-1α: NRF2 and PGC-1α cooperate to drive mitochondrial biogenesis

• p62/SQSTM1: p62 phosphorylation enhances NRF2 by disrupting KEAP1 binding

Therapeutic Implications

NRF2 Activators

Challenges and Considerations

• Timing: Chronic vs. acute activation may have different outcomes

• Cell-Type Specificity: Targeting NRF2 to specific cell types may be beneficial

• Cancer Risk: Chronic NRF2 activation may promote tumor growth (dual nature)

• Dose-Response: Optimal dosing regimens unclear for neurodegeneration

Combination Therapies

• NRF2 + mitochondrial antioxidants (CoQ10, MitoQ)

• NRF2 + autophagy enhancers (rapamycin, trehalose)

• NRF2 + anti-inflammatory agents (minocycline, NSAIDs)

• NRF2 + neurotrophic factors (BDNF, GDNF)

Animal Models

Knockout Studies

• Nrf2−/− mice: Increased susceptibility to oxidative stress, shortened lifespan

• Neuron-specific Nrf2 knockout: Enhanced neurodegeneration in PD models

• Astrocyte-specific Nrf2 knockout: Reduced neuroprotection, increased inflammation

Transgenic Models

• Nrf2-overexpressing mice: Protected against MPTP, 6-OHDA, Aβ toxicity

• Keap1 knockout mice: Constitutive NRF2 activation, protected from oxidative damage

• Human NRF2 knock-in: Enhanced stress resistance

Key Findings

• Nrf2 deletion accelerates neurodegeneration in multiple models

• NRF2 activation protects dopaminergic neurons from MPTP toxicity^{4NRF2 activation protects against oxidative stress and dopaminergic neuron loss in Parkinson's disease models2019 · Nat Neurosci · PMID 31391549Open reference}

• Astrocyte NRF2 is sufficient for neuroprotection

• Timing of NRF2 activation critical for therapeutic benefit

Key Publications

^{1The NRF2 regulatory network and its dysregulation in toxicity, injury, and disease2020 · Annu Rev Pharmacol Toxicol · PMID 31415175Open reference}: The NRF2 regulatory network and its dysregulation in toxicity, injury, and disease. Annu Rev Pharmacol Toxicol. 2020;60:401-427. ^{1The NRF2 regulatory network and its dysregulation in toxicity, injury, and disease2020 · Annu Rev Pharmacol Toxicol · PMID 31415175Open reference}(https://pubmed.ncbi.nlm.nih.gov/31415175/) ^{2KEAP1-NRF2 signaling in the heart: From basic science to clinical translation2021 · Nat Rev Cardiol · PMID 34267371Open reference}: KEAP1-NRF2 signaling in the heart: From basic science to clinical translation. Nat Rev Cardiol. 2021;18(12):759-774. ^{2KEAP1-NRF2 signaling in the heart: From basic science to clinical translation2021 · Nat Rev Cardiol · PMID 34267371Open reference}(https://pubmed.ncbi.nlm.nih.gov/34267371/) ^{2KEAP1-NRF2 signaling in the heart: From basic science to clinical translation2021 · Nat Rev Cardiol · PMID 34267371Open reference}0: NRF2 as a therapeutic target in neurodegenerative diseases. Neurotherapeutics. 2020;17(1):62-80. ^{3NRF2 as a therapeutic target in neurodegenerative diseases2020 · Neurotherapeutics · PMID 31808092Open reference}(https://pubmed.ncbi.nlm.nih.gov/31808092/) ^{2KEAP1-NRF2 signaling in the heart: From basic science to clinical translation2021 · Nat Rev Cardiol · PMID 34267371Open reference}1: NRF2 activation protects against oxidative stress and dopaminergic neuron loss in Parkinson’s disease models. Nat Neurosci. 2019;22(8):1246-1258. ^{4NRF2 activation protects against oxidative stress and dopaminergic neuron loss in Parkinson's disease models2019 · Nat Neurosci · PMID 31391549Open reference}(https://pubmed.ncbi.nlm.nih.gov/31391549/)

Background

The study of Nrf2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• Oxidative Stress Pathway

• Neuroinflammation Pathway

• Alzheimer’s Disease

• Parkinson’s Disease

• Huntington’s Disease

• Amyotrophic Lateral Sclerosis

• Mitochondrial Dysfunction Pathway

• Multiple Sclerosis

External Links

• NCBI Gene - NRF2

• UniProt - NRF2

• Ensembl - NFE2L2

• ARE Atlas

Brain Atlas Resources

• Allen Human Brain Atlas: Expression data for NFE2L2

• Allen Cell Type Atlas: Cell type expression data

• BrainSpan Atlas: Developmental transcriptome data